Tiziana Life Sciences Ltd
TLSA
$2.03
-$0.10-4.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.78% | 26.68% | 7.03% | -4.51% | -15.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.93% | 1.43% | -12.18% | -14.03% | -15.81% |
| Operating Income | -16.93% | -1.43% | 12.18% | 14.03% | 15.81% |
| Income Before Tax | 13.29% | 7.99% | 2.88% | 9.23% | 14.85% |
| Income Tax Expenses | 45.88% | -165.24% | -1,187.53% | -1,828.29% | -- |
| Earnings from Continuing Operations | 6.46% | 21.37% | 32.94% | 31.19% | 29.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.46% | 21.37% | 32.94% | 31.19% | 29.60% |
| EBIT | -16.93% | -1.43% | 12.18% | 14.03% | 15.81% |
| EBITDA | -16.95% | -1.42% | 12.21% | 14.07% | 15.84% |
| EPS Basic | 14.97% | 26.78% | 35.92% | 32.24% | 28.86% |
| Normalized Basic EPS | -7.47% | 4.60% | 14.98% | 18.46% | 21.63% |
| EPS Diluted | 14.97% | 26.78% | 35.92% | 32.24% | 28.86% |
| Normalized Diluted EPS | -7.47% | 4.60% | 14.98% | 18.46% | 21.63% |
| Average Basic Shares Outstanding | 10.35% | 7.23% | 4.10% | 1.64% | -0.78% |
| Average Diluted Shares Outstanding | 10.35% | 7.23% | 4.10% | 1.64% | -0.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |